Â鶹´«Ã½ÊÓƵÍøÕ¾

The funding success adds to an unprecedented summer that saw Â鶹´«Ã½ÊÓƵÍøÕ¾ spinout companies raise £265 million of investment which could transform patient outcomes.

Founded in 2015 through a partnership between Â鶹´«Ã½ÊÓƵÍøÕ¾B and F Prime Capital Partners, Orchard Therapeutics is based on research arising from the groups of Professor Bobby Gaspar and Professor Adrian Thrasher at the Â鶹´«Ã½ÊÓƵÍøÕ¾ GOS Institute of Child Health. Â鶹´«Ã½ÊÓƵÍøÕ¾B is the part of Â鶹´«Ã½ÊÓƵÍøÕ¾ Innovation & Enterprise that specialises in commercialising technology.

Orchard's development programmes focus on restoring normal gene function in primary immune deficiencies, metabolic diseases and haematological disorders.Ìý

This pioneering technology uses a sample of the patient's own stem cells, which are modified with a functioning copy of the missing or faulty gene before being transplanted back into the patient's body.Ìý

Using the patient's own (autologous) cells removes the need to search for a matching stem cell donor, which can take months or even years.

Orchard's lead programme is for the treatment of the rare and fatal disorder called severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), sometimes referred to as "bubble baby" syndrome in the press. Children with the disorder must be protected from any infections due to their highly fragile immune system.

"Rare diseases like the one's Orchard were established to develop treatments for, particularly rare childhood diseases, are often underfunded but this demonstrates peoples' commitment to changing that with the ultimate goal of improving the lives of very sick adults and children. I am extremely proud that Orchard has come so far in only three years," said Professor Thrasher.

Prior to the IPO, the Company had already raised $150 million Series C financing in August 2018 and $110m from a Series B round that completed in December 2017 to which the Â鶹´«Ã½ÊÓƵÍøÕ¾ Technology Fund (Â鶹´«Ã½ÊÓƵÍøÕ¾TF) contributed. Â鶹´«Ã½ÊÓƵÍøÕ¾TF is a £53m fund established by Â鶹´«Ã½ÊÓƵÍøÕ¾B and Albion Capital to invest in commercialisable technologies emerging from Â鶹´«Ã½ÊÓƵÍøÕ¾.

Dr Anne Lane, Â鶹´«Ã½ÊÓƵÍøÕ¾B Interim Managing Director commented, "Over the last ten years alone, Â鶹´«Ã½ÊÓƵÍøÕ¾B has helped the Â鶹´«Ã½ÊÓƵÍøÕ¾ community commercialise its world-leading, world-changing technologies and innovations into spinout companies that have collectively raised in excess of £1 billion investment."

"We're thrilled at Orchard's success and this is in no small part due to the innovative, hard work of Â鶹´«Ã½ÊÓƵÍøÕ¾ researchers and the foresight of the Â鶹´«Ã½ÊÓƵÍøÕ¾B team in recognising the potential investment opportunity."

Three other Â鶹´«Ã½ÊÓƵÍøÕ¾ spinout companies that are working to deliver advanced therapeutics to treat a range of diseases and have benefitted from substantial investment this summer include Autolus Therapetics Ltd, Athena Vision Ltd (acquired in the formation of MeiraGTx) and Freeline Ltd.

Autolus Therapeutics Ltd, based on advanced cell programming technology pioneered by Dr Martin Pule (Â鶹´«Ã½ÊÓƵÍøÕ¾ Cancer Institute), made its debut on the NASDAQ in June, raising $160 million investment.

MeiraGTx Holdings plc, a London and New York-based clinical stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases, raised $75 million at the close of its initial public offering on the NASDAQ.

The company was founded in the UK in 2015 in a series of deals which combined Â鶹´«Ã½ÊÓƵÍøÕ¾B spinout Athena Vision and certain assets of Kadmon Corporation, LLC a US specialty pharmaceutical company.

Also in June, Freeline Therapeutics, a clinical-stage company focused on treating chronic systemic diseases with liver-targeted gene therapy developed by Professor Amit Nathwani (Â鶹´«Ã½ÊÓƵÍøÕ¾ Cancer Institute), announced that it had raised over £88 million of new capital in a Series B financing.

In addition, MeiraGTx and Freeline have benefitted from investment from the Â鶹´«Ã½ÊÓƵÍøÕ¾ Technology Fund. The Fund has been so successful, that is it looking to establish a subsequent fund only three years after its launch.

Dr Celia Caulcott, Â鶹´«Ã½ÊÓƵÍøÕ¾ Vice-Provost (Enterprise), said:Ìý "The phenomenal accomplishment of raising over £430 million to bring new gene therapies to clinic, demonstrates the immense value of supporting each other and working collaboratively across the Â鶹´«Ã½ÊÓƵÍøÕ¾ community and partner organisations.

"Â鶹´«Ã½ÊÓƵÍøÕ¾ Innovation & Enterprise are building on this success together by continuing to bring Â鶹´«Ã½ÊÓƵÍøÕ¾'s amazing ideas to market, addressing some of the world's toughest challenges and creating true impact."

Links

• Â鶹´«Ã½ÊÓƵÍøÕ¾B
• Â鶹´«Ã½ÊÓƵÍøÕ¾ Innovation & Enterprise

Image

• DNA (Credit: )

Media contact

Bex Caygill

°Õ±ð±ô:Ìý+44 (0)20 3108 3846

Email: r.caygill [at] ucl.ac.uk